文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Beneficial effect of temporary methotrexate interruption on B and T cell responses upon SARS-CoV-2 vaccination in patients with rheumatoid arthritis or psoriatic arthritis.

作者信息

Martínez-Fleta Pedro, Vicente-Rabaneda Esther F, Triguero-Martínez Ana, Roy-Vallejo Emilia, Uriarte-Ecenarro Miren, Gutiérrez-Rodríguez Francisco, Quiroga-Colina Patricia, Romero-Robles Ana, Montes Nuria, García-Castañeda Noelia, Mejía-Abril Gina P, García-Vadillo Jesús A, Llorente-Cubas Irene, Villagrasa José R, Serra López-Matencio José M, Ancochea Julio, Urzainqui Ana, Esparcia-Pinedo Laura, Alfranca Arantzazu, de la Fuente Hortensia, García-Vicuña Rosario, Sánchez-Madrid Francisco, González-Álvaro Isidoro, Castañeda Santos

机构信息

Department of Immunology, Hospital Universitario de La Princesa IIS-Princesa (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain.

Department of Rheumatology, Hospital Universitario de La Princesa IIS-Princesa (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain.

出版信息

NPJ Vaccines. 2024 Jan 30;9(1):21. doi: 10.1038/s41541-024-00805-3.

DOI:10.1038/s41541-024-00805-3
PMID:38291047
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10827732/
Abstract

B and T cell responses were evaluated in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) after 1 or 2 weeks of methotrexate (MTX) withdrawal following each COVID-19 vaccine dose and compared with those who maintained MTX. Adult RA and PsA patients treated with MTX were recruited and randomly assigned to 3 groups: MTX-maintenance (n = 72), MTX-withdrawal for 1 week (n = 71) or MTX-withdrawal for 2 weeks (n = 73). Specific antibodies to several SARS-CoV-2 antigens and interferon (IFN)-γ and interleukin (IL)-21 responses were assessed. MTX withdrawal in patients without previous COVID-19 was associated with higher levels of anti-RBD IgG and neutralising antibodies, especially in the 2-week withdrawal group and with higher IFN-γ secretion upon stimulation with pools of SARS-CoV-2 S peptides. No increment of RA/PsA relapses was detected across groups. Our data indicate that two-week MTX interruption following COVID-19 vaccination in patients with RA or PsA improves humoral and cellular immune responses.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d0/10827732/887e55ccbcc9/41541_2024_805_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d0/10827732/07a17a405427/41541_2024_805_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d0/10827732/03e59520318b/41541_2024_805_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d0/10827732/9cf2b13ef330/41541_2024_805_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d0/10827732/89eb53b9c7a7/41541_2024_805_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d0/10827732/887e55ccbcc9/41541_2024_805_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d0/10827732/07a17a405427/41541_2024_805_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d0/10827732/03e59520318b/41541_2024_805_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d0/10827732/9cf2b13ef330/41541_2024_805_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d0/10827732/89eb53b9c7a7/41541_2024_805_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d0/10827732/887e55ccbcc9/41541_2024_805_Fig5_HTML.jpg

相似文献

[1]
Beneficial effect of temporary methotrexate interruption on B and T cell responses upon SARS-CoV-2 vaccination in patients with rheumatoid arthritis or psoriatic arthritis.

NPJ Vaccines. 2024-1-30

[2]
Impact of methotrexate on humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis.

Clin Exp Med. 2023-12

[3]
Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial.

Ann Rheum Dis. 2022-6

[4]
Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.

Front Immunol. 2022-2-28

[5]
Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID.

RMD Open. 2024-10-7

[6]
Janus kinase (JAK) inhibitors significantly reduce the humoral vaccination response against SARS-CoV-2 in patients with rheumatoid arthritis.

Clin Rheumatol. 2022-12

[7]
Methotrexate significantly reduces the humoral vaccination response against SARS-CoV-2 in older but not younger patients with rheumatoid arthritis.

Rheumatol Int. 2022-6

[8]
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination.

RMD Open. 2022-9

[9]
Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis.

Front Immunol. 2022

[10]
ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients.

Front Immunol. 2021

引用本文的文献

[1]
Severe Respiratory Infections in Rheumatoid Arthritis Patients: An Observational Study of 528 Patients from a Single University Hospital.

J Clin Med. 2025-2-11

[2]
Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID.

RMD Open. 2024-10-7

[3]
Effectiveness and Safety of the COVID-19 Vaccine in Patients with Rheumatoid Arthritis in a Real-World Setting.

Vaccines (Basel). 2024-6-18

本文引用的文献

[1]
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5.

Arthritis Rheumatol. 2023-1

[2]
Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials.

Lancet Rheumatol. 2022-11

[3]
Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination.

RMD Open. 2022-10

[4]
Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study.

Lancet Rheumatol. 2022-11

[5]
Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls.

Ann Rheum Dis. 2023-2

[6]
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination.

RMD Open. 2022-9

[7]
Elevated serum IgA following vaccination against SARS-CoV-2 in a cohort of high-risk first responders.

Sci Rep. 2022-9-2

[8]
Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 Vaccines.

Front Immunol. 2022

[9]
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.

Lancet Respir Med. 2022-9

[10]
Does an adjustment to the dosing and timing of immunomodulatory drugs alter the immunogenicity of the COVID-19 vaccines in patients with autoimmune and inflammatory rheumatic disease (AIIRD)?

RMD Open. 2022-5

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索